Bioqual

Bioqual Book Value per Share

The Book Value per Share of Bioqual (BIOQ) as of Sep 27, 2026 is 36.23 USD. In the previous year, Book Value per Share was 40.42 USD — a change of -10.36% (lower).

Book Value per Share

36.23USD

YoY

-10.36%

Last updated:

Book Value per Share of Bioqual is 2026 36.23 USD. Book Value per Share of Bioqual was 2025 40.42 USD. It decreases by -10.36% lower compared to the previous year.

The Bioqual Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2019
27.46 USD
Jan 1, 2020
31.51 USD
Jan 1, 2021
37.49 USD
Jan 1, 2022
42.12 USD
Jan 1, 2023
42.05 USD
Jan 1, 2024
42.10 USD
Jan 1, 2025
40.42 USD
Jan 1, 2026
36.23 USD
The Bioqual Book Value per Share history
YEARBook Value per ShareYoY
36.23USD-10.36%
40.42USD-3.97%
42.10USD+0.10%
42.05USD-0.16%
42.12USD+12.35%
37.49USD+18.98%
31.51USD+14.73%
27.46USD+11.40%
24.65USD+16.57%
21.15USD+23.19%
17.17USD+20.05%
14.30USD+15.62%
12.37USD—
Access this data via the Eulerpool API

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioqual stock

Book Value per Share of Bioqual is 36.23 USD in 2026.

Book Value per Share of Bioqual changed from 40.42 USD to 36.23 USD, representing a -10.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Bioqual since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

Balance Sheet — Bioqual

All Key Metrics — Bioqual